SAN JOSE, Calif., Sept. 8, 2019 /PRNewswire/ -- Aridis
Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical
company focused on the discovery and development of novel
anti-infective therapies to treat life-threatening bacterial
infections, announced today that Vu
Truong, Ph.D., Chief Executive Officer, will present at the
H.C. Wainwright 21st Annual Global Investment
Conference.
Date: Tuesday, September 10,
2019
Time: 12:30 pm Eastern
Time
Location: Lotte New York Palace Hotel
About Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives
to be used as add-on treatments to standard-of-care antibiotics.
The Company is utilizing its proprietary MabIgX® technology
platform to rapidly identify rare, potent antibody-producing
B-cells from patients who have successfully overcome an infection
to produce mAbs. These mAbs are already of human origin and
functionally optimized for high potency by the donor's immune
system; hence, they do not require genetic engineering or further
optimization to achieve full functionality. MabIgX® also allows for
the selection of any antibody isotype depending on the optimal
effector function required for treating the target infection. By
bypassing the humanization and binding sequence optimization steps,
and the entire process of generation of genetically engineered
antibody producing cell lines, MabIgX® enables high gross-margins
and expedited progression to clinical development.
The Company has generated multiple clinical stage mAbs targeting
bacteria that cause life-threatening infections such as
VAP and HAP. The use of mAbs as anti-infective treatments
represents an innovative therapeutic approach that harnesses the
human immune system to fight infections and is designed to overcome
the deficiencies associated with the current standard of care which
is broad spectrum antibiotics. Such deficiencies include, but are
not limited to, increasing drug resistance, short duration of
efficacy, disruption of the normal flora of the human microbiome
and lack of differentiation among current treatments. The mAb
portfolio is complemented by a non-antibiotic novel mechanism small
molecule anti-infective candidate being developed to treat lung
infections in cystic fibrosis patients. The company's pipeline is
highlighted below:
Aridis' Pipeline
AR-301 (VAP). AR-301 is a fully human
immunoglobulin 1, or IgG1, mAb currently in Phase 3 clinical
development targeting gram-positive S.
aureus alpha-toxin in VAP patients.
AR-101 (HAP). AR-101 is a fully human
immunoglobulin M, or IgM, mAb targeting P.
aeruginosa liposaccharides serotype O11, which accounts
for approximately 22% of all P.
aeruginosa hospital acquired pneumonia cases
worldwide.
AR-501 (cystic fibrosis). AR-501 is an inhaled
formulation of gallium citrate with broad-spectrum anti-infective
activity being developed to treat chronic lung infections in cystic
fibrosis patients. This program is currently in a Phase 1/2a
clinical study in healthy volunteers and CF patients.
AR-401 (blood stream infections). AR-401 is a
fully human mAb preclinical program aimed at treating infections
caused by gram-negative Acinetobacter baumannii.
AR-201 (RSV infection). AR-201 is a fully human IgG1
mAb preclinical program aimed at neutralizing diverse clinical
isolates of respiratory syncytial virus (RSV).
For additional information on Aridis Pharmaceuticals, please
visit https://aridispharma.com/.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties.
These statements may be identified by the use of words such as
"anticipate," "believe," "forecast," "estimated" and "intend" or
other similar terms or expressions that concern Aridis'
expectations, strategy, plans or intentions. These forward-looking
statements are based on Aridis' current expectations and actual
results could differ materially. There are a number of
factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. These
factors include, but are not limited to, the timing of regulatory
submissions, Aridis' ability to obtain and maintain regulatory
approval of its existing product candidates and any other product
candidates it may develop, approvals for clinical trials may be
delayed or withheld by regulatory agencies, risks relating to the
timing and costs of clinical trials, risks associated with
obtaining funding from third parties, management and employee
operations and execution risks, loss of key personnel, competition,
risks related to market acceptance of products, intellectual
property risks, risks associated with the uncertainty of future
financial results, Aridis' ability to attract collaborators and
partners and risks associated with Aridis' reliance on third party
organizations. While the list of factors presented here is
considered representative, no such list should be considered to be
a complete statement of all potential risks and uncertainties.
Unlisted factors may present significant additional obstacles to
the realization of forward-looking statements. Actual results could
differ materially from those described or implied by such
forward-looking statements as a result of various important
factors, including, without limitation, market conditions and the
factors described under the caption "Risk Factors" in Aridis' 10-K
for the year ended December 31,
2018 and Aridis' other filings made with the Securities and
Exchange Commission. Forward-looking statements included
herein are made as of the date hereof, and Aridis does not
undertake any obligation to update publicly such statements to
reflect subsequent events or circumstances.
Contact:
Investor Relations
Jason Wong
Blueprint Life Science Group
jwong@bplifescience.com
(415) 375-3340 Ext. 4
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aridis-pharmaceuticals-to-present-at-the-hc-wainwright-21st-annual-global-investment-conference-on-september-10-2019-300913758.html
SOURCE Aridis Pharmaceuticals, Inc.